Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 139.00 GBp
Change Today -0.50 / -0.36%
Volume 55.3K
SUMM On Other Exchanges
Symbol
Exchange
Berlin
London
OTC US
NASDAQ GM
As of 11:38 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

summit therapeutics plc (SUMM) Snapshot

Open
139.50 GBp
Previous Close
139.50 GBp
Day High
140.50 GBp
Day Low
138.50 GBp
52 Week High
03/2/15 - 185.00 GBp
52 Week Low
07/22/14 - 101.25 GBp
Market Cap
84.8M
Average Volume 10 Days
82.7K
EPS TTM
-0.33 GBp
Shares Outstanding
61.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUMMIT THERAPEUTICS PLC (SUMM)

Related News

No related news articles were found.

summit therapeutics plc (SUMM) Related Businessweek News

No Related Businessweek News Found

summit therapeutics plc (SUMM) Details

Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focusses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a fatal muscle wasting disease; and infections caused by Clostridium difficile bacteria (CDI). The company develops SMT C1100, an utrophin modulator that is in Phase Ib trial for the treatment of DMD; and SMT 19969, a novel antibiotic, which is in Phase II placebo controlled proof of concept clinical trial for the treatment of CDI. It has a technology license agreement with Bristol-Myers Squibb to access the Seglin technology for the identification and development of drug candidates. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc is headquartered in Abingdon, the United Kingdom.

23 Employees
Last Reported Date: 03/5/15

summit therapeutics plc (SUMM) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: 330.0K GBP
Chief Financial Officer
Total Annual Compensation: 198.5K GBP
Compensation as of Fiscal Year 2015.

summit therapeutics plc (SUMM) Key Developments

Summit Therapeutics plc Presents at Master Investor 2015 Conference, Apr-25-2015

Summit Therapeutics plc Presents at Master Investor 2015 Conference, Apr-25-2015 . Venue: Business Design Centre, Upper Street, London, N1, United Kingdom. Speakers: Richard Pye, Director of Corporate Communications.

Summit Therapeutics plc expected to report Fiscal Year 2015 results on April 26, 2015. This event was calculated by Capital IQ (Created on April 20, 2015).

Summit Therapeutics plc expected to report Fiscal Year 2015 results on April 26, 2015. This event was calculated by Capital IQ (Created on April 20, 2015).

Summit Therapeutics plc Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 11:20 AM

Summit Therapeutics plc Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-15-2015 11:20 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Glyn O. Edwards, Chief Executive Officer and Executive Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SUMM:LN 139.00 GBp -0.50

SUMM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SUMM.
View Industry Companies
 

Industry Analysis

SUMM

Industry Average

Valuation SUMM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUMMIT THERAPEUTICS PLC, please visit www.summitplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.